English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech (Sci&Research)
駛入創新時代的「快車道」,德琪醫藥出席第39屆摩根大通年度健康醫療大會
Jan 18, 2021 11:49 HKT
中国抗体SN1011之I期临床试验完成首例健康受试者给药
Jan 18, 2021 08:32 HKT
中國抗體SN1011之I期臨床試驗完成首例健康受試者給藥
Jan 18, 2021 08:31 HKT
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China
Jan 18, 2021 08:30 HKT
花旗首次覆蓋德琪醫藥(6996.HK),給予「買入」評級,目標價32.80港元
Jan 14, 2021 08:40 HKT
APOLLOMICS(冠科美博)UPROLESELAN(APL-106)注射液獲得國家CDE突破性療法認定
Jan 07, 2021 20:12 HKT
APOLLOMICS(冠科美博)UPROLESELAN(APL-106)注射液获得国家CDE突破性疗法认定
Jan 07, 2021 20:11 HKT
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Jan 07, 2021 20:10 HKT
Azelis significantly increases its market presence in Vietnam through the acquisition of a majority shareholding in MKVN Chemicals and Viet Chemi
Jan 05, 2021 14:35 HKT
Sự hiện diện của Azelis trên thị trường Việt Nam đã được củng cố sâu sắc sau thương vụ thu mua đa số cổ phần tại MKVN Chemicals và Viet Chemi
Jan 05, 2021 14:30 HKT
AIM ImmunoTech宣布其药物Ampligen的ME/CFS临床试验已开始接受COVID-19长期患者的注册
Dec 24, 2020 21:00 HKT
AIM ImmunoTech宣布其藥物Ampligen的ME/CFS臨床試驗已開始接受COVID-19長期患者的註冊
Dec 24, 2020 21:00 HKT
AIM ImmunoTech Announces that the ME/CFS Clinical Trial of its Drug Ampligen is Open for Enrollment to COVID-19 'Long Haulers'
Dec 24, 2020 21:00 HKT
China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level
Dec 21, 2020 19:00 HKT
賽生藥業與Y-mAbs就DANYELZA® (naxitamab-gqgk)和omburtamab兩款藥物達成大中華區產品授權合約
Dec 18, 2020 22:08 HKT
赛生药业与Y-mAbs就DANYELZA (naxitamab-gqgk)和omburtamab两款药物达成大中华区产品许可协议
Dec 18, 2020 22:07 HKT
华领医药成功完成III期注册临床研究 公布多扎格列艾汀与二甲双胍联合用药临床试验DAWN研究(HMM0302)的52周结果
Dec 18, 2020 09:17 HKT
華領醫藥成功完成III期註冊臨床研究 公佈多扎格列艾汀與二甲雙胍聯合用藥臨床試驗DAWN研究(HMM0302)的52週結果
Dec 18, 2020 09:16 HKT
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial
Dec 18, 2020 09:15 HKT
德琪医药渐入佳境 宜看中长线
Dec 17, 2020 08:40 HKT
<< Previous  Next >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: